Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2026.01.018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Daniel Ermann und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah Huntsman Cancer Institute, Hematology, Salt Lake City, UT. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Limited data exists comparing the efficacy of novel therapies containing brentuximab vedotin and/or checkpoint inhibitors to standard chemotherapy as treatment for relapsed/refractory classical Hodgkin Lymphoma. METHODS: In this study, we evaluated outcomes of 162 patients receiving second-line therapy, of which 64% (n = 104) were in the chemotherapy cohort and 36% (n = 58) in the novel therapy cohort. RESULTS: Over all responses for novel therapy and chemotherapy cohort were 76% versus 70% (P = .44), and complete response (CR) rates were 57% versus 46% (P = .40). The 2-year EFS rates were 72% versus 60% in novel therapy and chemotherapy cohort, respectively (P = .10). For patients who proceeded to autologous stem cell transplant (ASCT; n = 135), pretransplant CR predicted improved progression-free survival. In patients not proceeding to ASCT, prolonged 2-year EFS (86% vs. 33%, P < .01) was observed in those receiving novel therapy as second-line treatment. CONCLUSIONS: These data suggest improved outcomes in patients who receive novel agents compared to chemotherapy during second-line treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Utah Huntsman Cancer Institute, Hematology, Salt Lake City, UT.
- Virginia Commonwealth University Health Hematology, Richmond, VA.
- Karmanos Cancer Institute, Hematology, Detroit, MI.
- Tisch Cancer Institute at Mount Sinai, Hematology, NYC, NY.
- University of Alabama Medicine, Hematology, Birmingham, AL.
- Memorial Sloan Kettering Cancer Center, Hematology Division, New York, NY.
Zitieren
APA
Ermann, D., Vardell, V., Zacholski, E., Fegley, A., Modi, D., Fedak, K., Sundaram, S., Rajeeve, S., Goyal, G., Hatic, H., Torka, P., Ba Aqeel, S., Borogovac, A., MacDougall, K., Kothari, S., Kress, A., Travers, E., Chilakamarri, N., Brem, E., …, & Shah, H. (2026). Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.01.018
Vancouver
Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, et al. Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.01.018
BibTeX
@article{Ermann2026,
author = {Ermann, Daniel and Vardell, Victoria and Zacholski, Erin and Fegley, Amanda and Modi, Dipenkumar and Fedak, Kalub and Sundaram, Suchitra and Rajeeve, Sridevi and Goyal, Gaurav and Hatic, Haris and Torka, Pallawi and Ba Aqeel, Sheeba and Borogovac, Azra and MacDougall, Kira and Kothari, Shalin and Kress, Anna and Travers, Elizabeth and Chilakamarri, Nitin and Brem, Elizabeth and Ayyappan, Sabarish and Sigmund, Audrey and Bond, David and Fitzgerald, Lindsey and Wagner, Charlotte and Hu, Boyu and Stephens, Deborah M and Shah, Harsh},
title = {Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.01.018}
}
EUVIMED